Seeking Alpha

Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3...

Zipharm Oncology (ZIOP) +5.7% after providing positive Phase 3 trial data for its Picasso 3 sarcoma drug. The results correlate with positive data reported in February. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|